Table 3. [Part 3]. Description of Studies in Eastern Mediterranean Region Office (EMRO) and Middle Eastern Countries That Met Our Eligibility Criteria.
| Country | Pub. year | Male, % | Sample Size | HBsAg Prevalence (95% CI) |
|---|---|---|---|---|
| Saudi Arabia (E and M) | ||||
| Bashawri, L. A. | 2004 | NR | 13,443 | 2.28 (2.04 – 2.51) |
| El Beltagy, K. E. | 2008 | 100 | 3,192 | 3 (2.41 – 3.58) |
| El-Hazmi, M. M. | 2004 | 99 | 24,173 | 1.53 (1.37 – 1.68) |
| Mohammed Abdullah, S. | 2013 | NR | 29,949 | 3.8 (3.58 – 4.01) |
| Al-Bahrani, A. | 2001 | NR | 95,539 | 3.27 (3.15 – 3.38) |
| Ayoola, A. E. | 2003 | NR | 14,883 | 5.4 (5.04 – 5.75) |
| Panhotra, B. R. | 2005 | NR | 26,606 | 1.9 (1.73 – 2.06) |
| Turkey (M) | ||||
| Acar, A. | 2010 | NR | 72,695 | 1.78 (1.68 – 1.87) |
| Akalin, S. | 2011 | NR | 50,521 | 0.97 (0.88 – 1.05) |
| Gurol, E. | 2006 | NR | 6,240,130 | 4.19 (4.17 – 4.2) |
| Kader, C. | 2010 | 95 | 16,362 | 0.5 (0.4 – 0.59) |
| Oner, S. | 2011 | 96.3 | 30,716 | 2.2 (2.04 – 2.35) |
| Sakarya, S. | 2004 | 96.5 | 37,866 | 1.5 (1.38 – 1.61) |
| Tigen, E. T. | 2015 | 93.9 | 68,393 | 1.54 (1.44 – 1.63) |
| Turan, H. | 2011 | 93.5 | 17,071 | 1.53 (1.34 – 1.71) |
| Mese, S. | 2013 | 97 | 6,200 | 0.3 (0.16 – 0.43) |
| Mutlu, B. | 2004 | NR | 29,049 | 2.3 (2.12 – 2.47) |
| Yemen (E and M) | ||||
| Alodini, A. Q. | 2014 | NR | 3,000 | 2.1 (1.59 – 2.61) |
| Haidar, N. A. | 2002 | NR | 7,868 | 9.8 (9.15 – 10.44) |
| Pooled prevalence (EMRO and middle eastern countries) a | - | - | 28,947,262 | 2.03 (1.79–2.26)b |
Abbreviations: E, EMRO countries; E and M, all countries from the two regions; M, middle eastern countries; NR, not reported.
aPooled estimate by random effects meta-analyses.
b95% confidence interval (in parentheses).